Last mentioned: Mar 17, 2026
Bioequivalence Studies
Projected commencement of studies required for regional regulatory filings.
Commercialization Agreement
Strategic partnership signed for Eurasian market distribution and sales.
Strategic Agreement Signed
BioNxt announces a commercialization deal for Cladribine ODF in the Eurasian region.
Patent Grants Confirmed
Patents for the ODF formulation are officially granted in Europe and Eurasia.
Regulatory Filings
Anticipated submission of product dossiers to regional health authorities.
Patent Grants
BioNxt receives official patent approvals for Cladribine ODF in Europe and Eurasia.
BioNxt Solutions has entered a strategic partnership to commercialize its Cladribine Oral Dissolvable Film (ODF) across Eurasia, following successful patent approvals in both Europe and the Eurasian region. This move positions the company to capture market share in the Multiple Sclerosis (MS) treatment space with a novel, patient-friendly delivery mechanism.
BioNxt Solutions has finalized a strategic agreement for the commercialization of its Cladribine Oral Dissolvable Film (ODF) in Eurasia. The deal follows critical patent grants in both Europe and Eurasia, marking a transition from development to market entry for the company's Multiple Sclerosis treatment platform.